Home>>Signaling Pathways>> Others>> Others>>Phenprocoumon

Phenprocoumon Sale

(Synonyms: 苯丙羟基香豆素) 目录号 : GC30607

An anticoagulant and vitamin K antagonist

Phenprocoumon Chemical Structure

Cas No.:435-97-2

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥589.00
现货
10mg
¥536.00
现货
50mg
¥1,428.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Phenprocoumon is an anticoagulant and vitamin K antagonist.1,2 It inhibits the activity of wild-type vitamin K epoxide reductase (VKOR; IC50 = 4.2 nM), as well as a variety of mutant VKORs (IC50s = 5.1-835 nM), in cell-based reporter assays.1 Phenprocoumon inhibits prothrombin complex synthesis in rats in a dose-dependent manner.2 Formulations containing phenprocoumon have previously been used in the prevention and treatment of thromboembolic disorders.

1.Chen, X., Jin, D.-Y., Stafford, D.W., et al.Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieuBlood132(18)1974-1984(2018) 2.Schmidt, W.E., and J?hnchen, E.Stereoselective drug distribution and anticoagulant potency of the enantiomers of phenprocoumon in ratsJ. Pharm. Pharmacol.29(5)266-271(1977)

Chemical Properties

Cas No. 435-97-2 SDF
别名 苯丙羟基香豆素
Canonical SMILES O=C1C(C(C2=CC=CC=C2)CC)=C(O)C3=CC=CC=C3O1
分子式 C18H16O3 分子量 280.32
溶解度 DMSO : ≥ 125 mg/mL (445.92 mM) 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 3.5674 mL 17.8368 mL 35.6735 mL
5 mM 0.7135 mL 3.5674 mL 7.1347 mL
10 mM 0.3567 mL 1.7837 mL 3.5674 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Phenprocoumon poisonings

Phenprocoumon is a derivative of coumarin, used as a preventative anticoagulant and in the treatment of thromboembolisms. On account of its pharmacodynamic and pharmacokinetic properties, strict surveillance of the patient is necessary. We report on two cases of undocumented administration of this active pharmaceutical ingredient. A 57-year-old woman was discovered by her husband in an inanimate state. The post-mortem examination revealed many extensive haematomas. On account of a suspicion of third-party negligence, an autopsy was performed the same day, during which was established that the cause of death was a clotting abnormality, the cause of which remained unclear. Toxicological analyses revealed a concentration of phenprocoumon of 7.8 mg/l. A 76-year-old man admitted himself to hospital immediately upon returning from a stay abroad. In hospital, extensive haematomas and a massive clotting abnormality (prothrombin ratio<10%) were discovered. A blood sample taken the following day yielded evidence of a phenprocoumon concentration of 3.1 mg/l. According to his general practitioner, no corresponding medications had been prescribed. Suspicion of foul play in the introduction of this active agent resulted in a police investigation. Both cases demonstrate the necessity of toxicological analyses in cases of clotting abnormalities.

Ginger-associated overanticoagulation by phenprocoumon

Objective: To report a case of ginger-phenprocoumon interaction resulting in an elevated international normalized ratio (INR) and epistaxis.
Case summary: A 76-year-old white European woman on long-term phenprocoumon therapy with an INR within the therapeutic range began using ginger products. Several weeks later, she developed an elevated INR up to 10 and epistaxis. The INR returned to the normal range after ginger was stopped and vitamin K1 was given.
Discussion: There have been a number of investigations resulting in conflicting opinions on the effect of ginger on hemostasis, specifically, platelet inhibition. Nevertheless, based on these investigations, recommendations have been issued to refrain from ingesting ginger and other herbals like garlic or ginkgo biloba in situations where bleeding may be critical. An objective causality assessment revealed that the adverse drug event as a result of the phenprocoumon and ginger interaction was probable.
Conclusions: As of writing, this was the first case report that may support an interaction between an oral anticoagulant and ginger together with a brief review of the literature on ginger and hemostasis. As this interaction was observed only by chance, this case highlights the importance of self-control of anticoagulation with coumarins particularly for the detection of unknown interactions.

Carbamazepine-phenprocoumon interaction

[Switching from acenocoumarol to phenprocoumon: step in personalised anticoagulation?]

Acenocoumarol and phenprocoumon are vitamin K antagonists (VKA) with average half-lives of 11 hours and 160 hours, respectively. They are used to treat and prevent thrombosis in mechanical cardiac valve replacement, atrial fibrillation and venous thromboembolism. There are historical regional differences in preferred VKA in the Netherlands. Safe and effective treatment requires the international normalized ratios (INRs) to be in the therapeutic range, and stable. Theoretically, the longer-acting phenprocoumon would yield a higher time in therapeutic range (TTR) and lower INR variability. In practice, switching from acenocoumarol to phenprocoumon eventually improves INR variability and in some patients TTR as well. However, during the preceding transition period, INRs are more often volatile and supratherapeutic. Furthermore, switching to an alternative VKA could weaken integrated care, as other healthcare providers are less experienced with it. Healthcare providers must coordinate an intended switch with the anticoagulation clinic.

[Phenprocoumon-associated necrotizing hepatitis]